Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 237

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 237
---
 of accounting used by the registrant, OmnigenicsAI, and all material accounting policy differences have been identified in converting APx’s historical financial statements to IFRS in the pro forma section, see “ — GAAP to IFRS conversion of APx’s financial information as of June 30, 2024 and for the twelve -month period ended June 30, 2024.” The adjustments presented in the unaudited pro forma combined consolidated financial information have been identified and presented to provide relevant information necessary for an understanding of the Combined Company after giving effect to the Business Combination. The unaudited pro forma combined consolidated financial information has been prepared assuming three alternative levels of redemption of SPAC Ordinary Shares into cash: • Scenario 1 — Assuming no redemptions for cash: This presentation assumes that no SPAC Shareholders exercise redemption rights with respect to their SPAC Ordinary Shares upon consummation of the Business Combination and assumes that the obligations under the Backstop Agreement will be satisfied by making a cash contribution in an amount of up to $10,000,000 to OmnigenicsAI Corp. See “ Certain Agreements Related to the Business Combination — Backstop Agreement;” • Scenario 2 — Assuming redemptions of 50% of the outstanding Public Shares for cash: This presentation assumes that holders of Public Shares exercise their redemption rights with respect to 50% of the Public Shares upon consummation of the Business Combination at a redemption price of approximately $11.60 per share (fair value as of June30, 2024). Scenario 2 includes all adjustments contained in Scenario 1 and presents additional adjustments to reflect the effect of the redemptions of 50% of the Public Shares and assumes that the obligations under the Backstop Agreement will be satisfied by making a cash contribution in an amount of up to $10,000,000 to OmnigenicsAI Corp. See “ Certain Agreements Related to the Business Combination — Backstop Agreement;” and • Scenario 3 — Assuming redemptions of 100% of outstanding Public Shares for cash: This presentation assumes that holders of Public Shares exercise their redemption rights with respect to a maximum of 100% of the Public Shares upon consummation of the Business Combination at a redemption price of approximately $11.60 per share (fair value as of June30, 2024). Scenario 3 includes all adjustments contained in Scenario1, presents additional adjustments to reflect the effect of the maximum redemptions and assumes that the obligations under the Backstop